IMPROVING METABOLIC PARAMETERS OF ANTIPSYCHOTIC CHILD TREATMENT (IMPACT)

改善抗精神病药物儿童治疗的代谢参数（影响）

• 批准号: 8167274
• 负责人: CHRISTOPH U CORRELL
• 金额: $ 0.64万
• 依托单位: FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-01 至 2011-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167274
• 关键词: 17 year old; Adolescent; Antipsychotic Agents; Child; Computer Retrieval of Information on Scientific Projects Database; Counseling; Funding; Generations; Grant; Hospitals; Institution; Life Style; Metabolic; Metformin; Patients; Randomized; Research; Research Personnel; Resources; Site; Source; United States National Institutes of Health; Weight Gain; improved

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This five-year, three-site study, entitled "Improving Metabolic Parameters of Antipsychotic Child Treatment", will evaluate two different strategies for reducing excessive weight gain associated with antipsychotic treatment in children and adolescents (8-17 years old). Two hundred forty patients (80 at NS-LIJ Zucker Hillside Hospital) will be randomized to one of three groups; A) Continuation of baseline SGA (second generation antipsychotic) + healthy lifestyle counseling; B) Continuation of baseline SGA + healthy lifestyle counseling + Metformin; C) Staggered switch from baseline SGA to Ariprozole + healthy lifestyle counseling.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 这项为期五年、三个地点的研究题为“改善抗精神病药物儿童治疗的代谢参数”，将评估两种不同的策略，以减少儿童和青少年（8-17 岁）与抗精神病药物治疗相关的体重过度增加。 240 名患者（其中 80 名来自 NS-LIJ Zucker Hillside 医院）将被随机分入三组中的一组； A) 继续基线SGA（第二代抗精神病药）+健康生活方式咨询； B) 继续基线SGA+健康生活方式咨询+二甲双胍； C) 从基线 SGA 交错切换到阿立丙唑 + 健康生活方式咨询。